biosig_rgb.png
BioSig Confirms No Exposure to Silicon Valley Bank
March 13, 2023 07:30 ET | BioSig Technologies, Inc.
Westport, CT, March 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
biosig_rgb.png
BioSig Regains Compliance With All Nasdaq Listing Standards
February 22, 2023 07:30 ET | BioSig Technologies, Inc.
Westport, CT, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering...
biosig_rgb.png
BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy
February 07, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly brings 15 years of public company...
biosig_rgb.png
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
January 19, 2023 08:30 ET | BioSig Technologies, Inc.
Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The...
biosig_rgb.png
BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology
January 10, 2023 08:30 ET | BioSig Technologies, Inc.
Westport, CT, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Leading Midwest healthcare system reports significant cost savings and noise reduction following evaluation of the PURE EP™ System Medical center...
biosig_rgb.png
Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
December 14, 2022 16:30 ET | BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
biosig_rgb.png
BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
December 14, 2022 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
biosig_rgb.png
BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology
December 06, 2022 08:30 ET | BioSig Technologies, Inc.
Westport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
InCarda Logo.png
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
November 07, 2022 07:00 ET | InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
Bio-Sig-Logo-horiz.jpg
BioSig Signs Master Research Agreement with Cleveland Clinic to Explore Expanded Applications for its Digital Signal Processing Technology
October 24, 2022 11:03 ET | BioSig Technologies, Inc.
Westport, CT, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Medical Center of Excellence to leverage the Company’s PURE EP™ System to further its research and educational objectives as a leader in cardiac...